NCT05498636

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Selinexor Combined With Prednisone, Etoposide, and Lenalidomide as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for Refractory Diffuse Large B-cell Lymphoma With p53 and/or c-Myc Expression

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 67 (estimated)
• Sponsor: The Affiliated Hospital of Qingdao University · Academic / Other
• Sex: All
• Age: 16 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase II multi-center prospective clinical trail which investigates the efficacy and safety of Selinexor combined with prednisone, etoposide and lenalidomide in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patient with high p53 and/or c-myc expression.

Conditions

• DLBCL

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Selinexor combined with Prednisone, Etoposide, and Lenalidomide	Selinexor combined with Prednisone, Etoposide, and Lenalidomide

Timeline

• Start date: 2022-10-01
• Primary completion: 2025-07-30
• Completion: 2025-12-31
• First posted: 2022-08-12
• Last updated: 2022-08-19

Locations

1 site across 1 country: China